ERBB2 and breast cancer: Although the mortality of BC remains stable, despite its increasing incidence, over 75% of deaths are caused by metastatic tumors that may express a different profile of clinically relevant biomarkers, such as estrogen receptor (ER), progesterone receptor (PR), and HER2, than the primary mass (3).